What's trending

5 most popular innovation stories in Houston this week

From Houston being named the most diverse city in the nation to an update from a fintech company, here's what news trended this week. Photo by PeopleImages

Editor's note: Heading into Easter Weekend, news might slow down a bit. However, last week was chock full of trending news — from entrepreneurs giving back to funding rounds closing. Check out what news readers were into this week.

Need more than just trending news on Fridays? Subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.

3 Houston entrepreneurs changing the world with their B2B startups

The Cannon hosted a B2B pitch night, and all three companies have a mission to change the world. Courtesy of The Cannon

I think it's safe to say that most B2B startups don't have sustainability or a mission-driven purpose at the core of their business model. In fact, it's probably safe to say that about any for-profit company of any size.

Three Houston entrepreneurs pitched their companies at The Cannon's recent B2B pitch night, and they all have something in common: They're not normal B2B startups. Each company has a mission to change the way we're doing something — from hiring to construction — in a way that's better for the world. Read the full story here.

Houston software company raises $16.3 million, TMCx opens applications, and more innovation news

TMCx is looking for members for its ninth cohort — and other Houston innovation news. Courtesy of TMCx

From rounds closing to accelerator applications opening, there's a lot of Houston innovation news that might not have reached your radar. Here's a roundup of short stories within tech and innovation in the Bayou City. Read the story here.

Houston crowned most diverse city in America by new report

The Bayou City has staked its claim as most diverse city in the nation. Photo by Tim Leviston/Getty Images

Last year, many locals cried foul when Houston was named the No. 2 most diverse city in the nation, behind — gasp! — Jersey City, New Jersey. But a new report confirms what we here already know: Houston is, indeed, the most diverse city in the country. Read the story here.

3 Houston innovators to know this week

This week's innovators to know represents a homecoming, an accelerator launch, and a call for tech education. Courtesy photos

This week's innovators to know span across industries — from sports tech to education, but they are all fighting for something here in Houston. Here's what they are focused on bringing to the Houston innovation ecosystem. Read the story here.

Houston fintech startup partners with local coworking space to grow investment opportunities

LetsLaunch, a Houston-based fundraising platform, has teamed up with The Cannon. Courtesy of LetsLaunch

A Houston fintech software company has joined forces with The Cannon to help connect its members to capital. LetsLaunch, a platform that allows for smaller investments from non-accredited investors, and The Cannon — along with its venture arm, Cannon Ventures — have officially entered a partnership as of this month.

"We're basically providing a transactional tool to allow Cannon Ventures to access more members who, legally, they couldn't access before," says Nick Carnrite, co-founder and CEO of LetsLaunch. "For us, it's a good thing because instead of having to go out and create a community of startups and investors, that gets brought to us." Read the story here.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News